Acadia Upgraded To Buy From Neutral At Goldman Sachs

Goldman Sachs analyst Salveen Richter upgraded Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a price target of $72, up from $45.

The analyst sees an "upward re-rating opportunity" for the shares on upcoming events, namely Nuplazid expansion into dementia-related psychosis and the Phase 3 CLARITY-2 results in major depressive disorder. On the latter, assuming a clinical impact to major depressive disorder from COVID-19, thus removing it from the model, the price target would be $62, representing 50% upside potential to current levels, Richter tells investors in a research note.

Further, the analyst believes Acadia's existing commercial business is "somewhat able to withstand" COVID-19 given its over two-year Nuplazid inventory and high proportion of distribution to patients via mail order.

The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from ...
more

The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at any time. The Fly team scours all sources of company news, from mainstream to cutting-edge, then filters out the noise to deliver short-form stories consisting of only market moving content. Follow @theflynews on Twitter. For a free trial, click here.